Promising combo aims to shrink tumors in elderly breast cancer patients
NCT ID NCT07589972
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of targeted drugs (trastuzumab and pertuzumab) plus a low-dose chemotherapy (vinorelbine) given before surgery to elderly patients (70+) with HER2-positive breast cancer. The goal is to see if this approach can completely eliminate cancer cells in the breast and lymph nodes. The trial will enroll 45 participants and monitor how well the tumors respond, with a focus on safety and effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- trastuzumab, pertuzumab, and vinorelbine
- What this could lead to
- If successful, this could offer a less toxic, effective pre-surgery treatment option for elderly patients with HER2-positive breast cancer, potentially improving outcomes without harsh side effects.
- What could go wrong
- This is a small, early-phase study with only 45 participants, so results may not apply broadly. The treatment may not work for everyone, and side effects from the chemotherapy and targeted drugs are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY-STAGE HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.